Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population

Emi Hamano, Minako Hijikata, Satoru Itoyama, Tran Quy, Nguyen Chi Phi, Hoang Thuy Long, Le Dang Ha, Vo Van Ban, Ikumi Matsushita, Hideki Yanai, Fumiko Kirikae, Teruo Kirikae, Tadatoshi Kuratsuji, Takehiko Sasazuki, Naoto Keicho, Emi Hamano, Minako Hijikata, Satoru Itoyama, Tran Quy, Nguyen Chi Phi, Hoang Thuy Long, Le Dang Ha, Vo Van Ban, Ikumi Matsushita, Hideki Yanai, Fumiko Kirikae, Teruo Kirikae, Tadatoshi Kuratsuji, Takehiko Sasazuki, Naoto Keicho

Abstract

We hypothesized that host antiviral genes induced by type I interferons might affect the natural course of severe acute respiratory syndrome (SARS). We analyzed single nucleotide polymorphisms (SNPs) of 2',5'-oligoadenylate synthetase 1 (OAS-1), myxovirus resistance-A (MxA), and double-stranded RNA-dependent protein kinase in 44 Vietnamese SARS patients with 103 controls. The G-allele of non-synonymous A/G SNP in exon 3 of OAS-1 gene showed association with SARS (p=0.0090). The G-allele in exon 3 of OAS-1 and the one in exon 6 were in strong linkage disequilibrium and both of them were associated with SARS infection. The GG genotype and G-allele of G/T SNP at position -88 in the MxA gene promoter were found more frequently in hypoxemic group than in non-hypoxemic group of SARS (p=0.0195). Our findings suggest that polymorphisms of two IFN-inducible genes OAS-1 and MxA might affect susceptibility to the disease and progression of SARS at each level.

References

    1. World Health Organization (2003), Consensus document on the epidemiology of severe acute respiratory syndrome (SARS), WHO/CDS/CSR/GAR/2003.11, Geneva
    1. Booth C.M., Matukas L.M., Tomlinson G.A., Rachlis A.R., Rose D.B., Dwosh H.A., Walmsley S.L., Mazzulli T., Avendano M., Derkach P., Ephtimios I.E., Kitai I., Mederski B.D., Shadowitz S.B., Gold W.L., Hawryluck L.A., Rea E., Chenkin J.S., Cescon D.W., Poutanen S.M., Detsky A.S. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. Jama. 2003;289:2801–2809.
    1. Chan J.W., Ng C.K., Chan Y.H., Mok T.Y., Lee S., Chu S.Y., Law W.L., Lee M.P., Li P.C. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS) Thorax. 2003;58:686–689.
    1. Lin M., Tseng H.K., Trejaut J.A., Lee H.L., Loo J.H., Chu C.C., Chen P.J., Su Y.W., Lim K.H., Tsai Z.U., Lin R.Y., Lin R.S., Huang C.H. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med. Genet. 2003;4:9.
    1. Ng M.H., Lau K.M., Li L., Cheng S.H., Chan W.Y., Hui P.K., Zee B., Leung C.B., Sung J.J. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J. Infect. Dis. 2004;190:515–518.
    1. Itoyama S., Keicho N., Quy T., Phi N.C., Long H.T., Ha le D., Ban V.V., Ohashi J., Hijikata M., Matsushita I., Kawana A., Yanai H., Kirikae T., Kuratsuji T., Sasazuki T. ACE1 polymorphism and progression of SARS. Biochem. Biophys. Res. Commun. 2004;323:1124–1129.
    1. Peiris J.S., Lai S.T., Poon L.L., Guan Y., Yam L.Y., Lim W., Nicholls J., Yee W.K., Yan W.W., Cheung M.T., Cheng V.C., Chan K.H., Tsang D.N., Yung R.W., Ng T.K., Yuen K.Y. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325.
    1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953–1966.
    1. Drosten C., Gunther S., Preiser W., van der Werf S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1967–1976.
    1. Kuiken T., Fouchier R.A., Schutten M., Rimmelzwaan G.F., van Amerongen G., van Riel D., Laman J.D., de Jong T., van Doornum G., Lim W., Ling A.E., Chan P.K., Tam J.S., Zambon M.C., Gopal R., Drosten C., van der Werf S., Escriou N., Manuguerra J.C., Stohr K., Peiris J.S., Osterhaus A.D. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362:263–270.
    1. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001;14:778–809.
    1. Haagmans B.L., Kuiken T., Martina B.E., Fouchier R.A., Rimmelzwaan G.F., van Amerongen G., van Riel D., de Jong T., Itamura S., Chan K.H., Tashiro M., Osterhaus A.D. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat. Med. 2004;10:290–293.
    1. Cinatl J., Morgenstern B., Bauer G., Chandra P., Rabenau H., Doerr H.W. Treatment of SARS with human interferons. Lancet. 2003;362:293–294.
    1. Hensley L.E., Fritz L.E., Jahrling P.B., Karp C.L., Huggins J.W., Geisbert T.W. Interferon-beta 1a and SARS coronavirus replication. Emerg. Infect. Dis. 2004;10:317–319.
    1. Spiegel M., Pichlmair A., Muhlberger E., Haller O., Weber F. The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein. J. Clin. Virol. 2004;30:211–213.
    1. Stroher U., DiCaro A., Li Y., Strong J.E., Aoki F., Plummer F., Jones S.M., Feldmann H. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J. Infect. Dis. 2004;189:1164–1167.
    1. Tan E.L., Ooi E.E., Lin C.Y., Tan H.C., Ling A.E., Lim B., Stanton L.W. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg. Infect. Dis. 2004;10:581–586.
    1. Zheng B., He M.L., Wong K.L., Lum C.T., Poon L.L., Peng Y., Guan Y., Lin M.C., Kung H.F. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma) J. Interferon Cytokine Res. 2004;24:388–390.
    1. Sainz B., Jr., Mossel E.C., Peters C.J., Garry R.F. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) Virology. 2004;329:11–17.
    1. Hijikata M., Ohta Y., Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt −88) correlated with the response of hepatitis C patients to interferon. Intervirology. 2000;43:124–127.
    1. Suzuki F., Arase Y., Suzuki Y., Tsubota A., Akuta N., Hosaka T., Someya T., Kobayashi M., Saitoh S., Ikeda K., Matsuda M., Takagi K., Satoh J., Kumada H. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepat. 2004;11:271–276.
    1. Knapp S., Yee L.J., Frodsham A.J., Hennig B.J., Hellier S., Zhang L., Wright M., Chiaramonte M., Graves M., Thomas H.C., Hill A.V., Thursz M.R. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003;4:411–419.
    1. Benech P., Mory Y., Revel M., Chebath J. Structure of two forms of the interferon-induced (2′–5′) oligo A synthetase of human cells based on cDNAs and gene sequences. Embo J. 1985;4:2249–2256.
    1. Lewontin R.C. On measures of gametic disequilibrium. Genetics. 1988;120:849–852.
    1. Rebouillat D., Hovanessian A.G. The human 2′,5′-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J. Interferon Cytokine Res. 1999;19:295–308.
    1. Ghosh A., Sarkar S.N., Rowe T.M., Sen G.C. A specific isozyme of 2′–5′ oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family. J. Biol. Chem. 2001;276:25447–25455.
    1. Ghosh S.K., Kusari J., Bandyopadhyay S.K., Samanta H., Kumar R., Sen G.C. Cloning, sequencing, and expression of two murine 2′–5′-oligoadenylate synthetases. Structure–function relationships. J. Biol. Chem. 1991;266:15293–15299.
    1. Mosca J.D., Pitha P.M. Transcriptional and posttranscriptional regulation of exogenous human beta interferon gene in simian cells defective in interferon synthesis. Mol. Cell. Biol. 1986;6:2279–2283.
    1. Diaz M.O., Ziemin S., Le Beau M.M., Pitha P., Smith S.D., Chilcote R.R., Rowley J.D. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc. Natl. Acad. Sci. USA. 1988;85:5259–5263.
    1. Cinatl J., Jr., Hoever G., Morgenstern B., Preiser W., Vogel J.U., Hofmann W.K., Bauer G., Michaelis M., Rabenau H.F., Doerr H.W. Infection of cultured intestinal epithelial cells with severe acute respiratory syndrome coronavirus. Cell. Mol. Life Sci. 2004;61:2100–2112.
    1. Hijikata M., Mishiro S., Miyamoto C., Furuichi Y., Hashimoto M., Ohta Y. Genetic polymorphism of the MxA gene promoter and interferon responsiveness of hepatitis C patients: revisited by analyzing two SNP sites (−123 and −88) in vivo and in vitro. Intervirology. 2001;44:379–382.
    1. Fernandez-Arcas N., Blanco A., Gaitan M.J., Nyqvist M., Alonso A., Reyes-Engel A. Differential transcriptional expression of the polymorphic myxovirus resistance protein A in response to interferon-alpha treatment. Pharmacogenetics. 2004;14:189–193.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa